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Abstract
Background: Tamoxifen has been US Food and Drug Administration–approved for primary prevention of breast cancer since 
1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the 
risk-benefit profiles of women who use chemoprevention outside of a clinical trial. We examined characteristics associated 
with initiation and discontinuation of tamoxifen for primary prevention of breast cancer within a large cohort of women 
with a first-degree family history of breast cancer.
Methods: This research was conducted within The Sister Study, a cohort of 50 884 US and Puerto Rican women age 35 to 
74 years enrolled from 2003 to 2009. Eligible women were breast cancer–free at enrollment and had a sister who had been 
diagnosed with breast cancer. Participants reported tamoxifen use, ages started and stopped taking tamoxifen, and total 
duration of use at enrollment. We identified 788 tamoxifen users and 3131 nonusers matched on age and year of enrollment 
who had no history of contraindicating factors (stroke, transient ischemic attack, cataract, endometrial or uterine cancer). 
Characteristics associated with tamoxifen initiation were evaluated with multivariable conditional logistic regression. All 
statistical tests were two-sided.
Results: Based on published risk-benefit indices, 20% of women who used tamoxifen had insufficient evidence that the 
benefits of tamoxifen outweigh the risk of serious side effects. After 4.5 years, 46% of women had discontinued tamoxifen.
Conclusions: While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to 
benefit, substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may 
attenuate benefits for breast cancer prevention.
An estimated 15% of US women age 35 to 79 years are eligible 
for breast cancer chemoprevention; however, less than 5% may 
have favorable risk-benefit profiles (1). Tamoxifen can decrease 
risk of invasive breast cancer up to 48% and was US Food and 
Drug Administration (FDA)–approved for primary prevention in 
1998 for women 35 years and older at high risk of breast cancer 
(typically determined by a five-year probability of developing 
invasive breast cancer greater than 1.67%) and low risk of seri-
ous side effects (including endometrial cancer, stroke, pulmo-
nary embolism, deep vein thrombosis, and cataract) (2–6). It is 
the only approved pharmacologic agent for breast cancer pre-
vention available to premenopausal women (7).
The US Preventive Services Task Force (USPSTF) recently 
published a recommendation statement for risk reduction of 






primary breast cancer that encourages clinicians to offer to pre-
scribe tamoxifen or raloxifene to reduce breast cancer risk (8). 
National estimates indicate that less than 1% of eligible women 
use tamoxifen for prevention (9). It is unknown why few women 
use tamoxifen for breast cancer prevention, although vasomotor 
symptoms, increased risk of adverse health effects, and difficul-
ties in estimating or communicating risk-benefit profiles can be 
deterrents.
Whether women who do use tamoxifen for breast can-
cer prevention are among those most likely to benefit is also 
unknown. In previous studies, willingness to use tamoxifen has 
not consistently been associated with invasive breast cancer risk 
(10–13). Further, substantial nonadherence to the recommended 
five-year course of tamoxifen has been reported in prevention 
trials. To date, there has been no large study of tamoxifen users 
outside of a trial setting to evaluate risk-benefit profiles or early 
discontinuation.
We examined risk-benefit profiles of women who used 
tamoxifen for primary breast cancer prevention and character-
istics associated with initiation and discontinuation among a 
sample of adult US and Puerto Rican women with a first-degree 
family history of breast cancer.
Methods
The Sister Study prospective cohort was designed to address 
genetic and environmental risk factors for breast cancer. From 
2003 to 2009, 50 884 US and Puerto Rican women age 35 to 
74  years were recruited through a national multimedia cam-
paign and network of recruitment volunteers, breast cancer 
professionals, and advocates. Eligible women had a sister who 
had been diagnosed with breast cancer but did not have breast 
cancer themselves. Participants completed baseline computer-
assisted telephone interviews on medical and family history, 
lifestyle factors, and demographics. All participants were asked, 
“Have you ever used tamoxifen or Nolvadex (these are taken to 
prevent breast cancer)?” at enrollment and reported ages they 
started and/or stopped using tamoxifen and their total dura-
tion of use. All participants provided informed consent. This 
research was approved by the Institutional Review Boards of 
the National Institute of Environmental Health Sciences, the 
National Institutes of Health, and the Copernicus Group.
Study Design
We identified 1046 women who reported ever using tamoxifen 
(“tamoxifen users”) at enrollment. Of these, 1038 women pro-
vided information on the age they started and stopped using 
tamoxifen. For comparison subjects, we randomly selected up to 
four women from the cohort who reported never using tamox-
ifen (“nonusers”) matched on age and year of enrollment to each 
tamoxifen user. An index age was defined as the age of tamox-
ifen initiation for each user and the corresponding age for her 
matched control patients. The index age allowed for compari-
sons between tamoxifen users and nonusers to be made relative 
to the time of tamoxifen initiation, rather than at enrollment 
when tamoxifen use could have influenced participant char-
acteristics (eg, postmenopausal hormone use, hysterectomy 
status, etc.).
We excluded women with a history of contraindicating med-
ical conditions as of the index age (n  =  52, including 41 cata-
ract, one stroke, five transient ischemic attack [TIA], four uterine 
cancer, one combination TIA, stroke, and cataract) or who par-
ticipated in a clinical trial of tamoxifen (n  =  173). Twenty-five 
women were excluded because of a diagnosis of lobular carci-
noma in situ that preceded tamoxifen use or missing date of 
breast cancer diagnosis. In total, 788 women contributed infor-
mation as tamoxifen users, of which 767 were matched with 
four nonusers and 21 matched with three (n = 3131) nonusers.
Participant Characteristics
Characteristics defined prior to the index age included smok-
ing, hysterectomy, oophorectomy, menopausal status, post-
menopausal hormone use, and raloxifene use. Characteristics 
at enrollment included demographics, general health, breast 
biopsy history, and BRCA1/2 testing. We calculated a five-year 
probability of developing invasive breast cancer with the SAS 
macro for the Breast Cancer Risk Assessment Tool (BCRAT) 
designed by the National Cancer Institute and the National 
Surgical Adjuvant Breast and Bowel Project (14–19), which uses 
information on age, age at menarche, nulliparity or age at first 
live birth, first-degree family history of breast cancer, breast 
biopsy history, and race/ethnicity (http://www.cancer.gov/
bcrisktool/).
Risk-Benefit Estimates
We categorized women according to a risk-benefit index pro-
posed by Gail et al. (16) and recently updated by Freedman et al. 
(20) that is recommended for patient counseling by the USPSTF 
(8) and the National Comprehensive Cancer Network (NCCN) 
(21). Briefly, the risk-benefit index classifies women according 
to the level of evidence (none, moderate, strong) for tamoxifen 
benefits (breast cancer and fracture prevention) to exceed the 
risk of serious side effects (endometrial cancer, stroke, pulmo-
nary embolism, deep vein thrombosis, and cataract) using age, 
five-year projected risk of invasive breast cancer, hysterectomy, 
and race. Detailed information on the construction of the index 
has been published (16,20). In our analysis, we used index age, 
hysterectomy status at index age, and five-year probability of 
invasive breast cancer risk calculated using age at enrollment 
because of a lack of age-specific information on breast biopsy 
history.
Among the 788 tamoxifen users, we characterized the risk-
benefit index for 742 (94%) women. In our sample, 131 women 
had a BCRAT score greater than or equal to 7.5% which exceeds 
the highest listed BCRAT category (7.0%). For analysis, these 
women were included in the 7.0% BCRAT category to preserve 
the maximum sample size; results were largely unchanged when 
they were alternatively excluded from analysis. Risk-benefit cat-
egories were not defined for 46 tamoxifen users for the following 
reasons: Categories have not been defined for Hispanic women 
younger than 50 years (n = 10), other race-ethnicities (n = 18), 
BCRAT scores of less than 1.5% (n = 12), or ages younger than 
35 years (n = 1). Finally, scores could not be calculated for five 
women missing components of the index.
Statistical Analysis
Odds ratios and 95% confidence intervals for characteristics 
associated with tamoxifen use were calculated with mul-
tivariable conditional logistic regression to account for the 
matched design. In analyses of tamoxifen users only, uncon-
ditional logistic regression was applied. Two-sided P values 
of less than or equal to .05 were considered to be statistically 
significant. Kaplan–Meier curves were produced to display 






tamoxifen discontinuation over five years with Stata 12 software 
(StataCorp., College Station, TX) (22). All other statistical analy-
ses were performed with SAS 9.3 (SAS Institute, Inc., Cary, NC).
Sensitivity Analyses
Sister Study eligibility precluded previous breast cancer diag-
nosis. Women with higher BCRAT scores and correspondingly 
favorable risk-benefit indices at the index age may have been 
disproportionately ineligible to participate if they developed 
breast cancer in the intervening years. Therefore, we performed 
sensitivity analyses to evaluate associations with the BCRAT 
score and risk-benefit index among tamoxifen users who began 
use within five years (n = 363) and two years (n = 120) of study 
enrollment and their matched nonusers (n = 1443 and n = 475, 
respectively).
BCRAT scores were calculated for age at study enrollment 
rather than tamoxifen initiation. To evaluate the sensitivity of 
results to possible changes in BCRAT score between these ages, 
we restricted the evaluation of the risk-benefit index to cur-
rent tamoxifen users (n = 272) for whom the interval between 
tamoxifen initiation and study enrollment (mean  =  2.6  years, 
SD = 1.9, IQR = 1–4) was shorter. Risk-benefit index categories 
were defined for 95% of this subgroup (n = 258).
Results
Tamoxifen Use for Breast Cancer Prevention
Among tamoxifen users, the mean age at tamoxifen initiation 
was 50.7 years (SD = 7.4). The median calendar year of tamoxifen 
initiation was 2001; the mode was 2000. Overall, 74% of classified 
tamoxifen users had a favorable (defined as moderate to strong 
evidence for benefits to exceed risks) risk-benefit profile and 
20% had no evidence that the benefits exceeded risks (Figure 1); 
the risk-benefit index could not be calculated for 6%. The risk-
benefit index distribution across calendar years is provided in 
Supplementary Table 1 (available online).
When stratified by factors contributing to the risk-benefit 
score (eg, hysterectomy, race, age), the proportion with insuffi-
cient evidence of net benefit varied between groups. Women who 
had hysterectomies prior to starting tamoxifen were 11 times 
more likely to have a favorable risk-benefit profile compared 
with women with an intact uterus (OR = 11.87, 95% CI = 5.94 to 
23.73). Younger women were likely to have a favorable risk-ben-
efit index; only three of the 321 women who started tamoxifen 
before age 50 years had no evidence of benefit. Compared with 
non-Hispanic whites, the 28 African American women were 65% 
less likely to have a favorable risk-benefit profile (OR = 0.35, 95% 
CI = 0.16 to 0.75) (Figure 1). These patterns were also apparent in 
sensitivity analyses restricted to current users (Supplementary 
Figure 1, available online).
 More than 90% of tamoxifen users were non-Hispanic 
white. African American and Hispanic women were 48% to 
59% less likely compared with Non-Hispanic white women to 
report use (OR = 0.41, 95% CI = 0.26 to 0.63 and OR = 0.52, 95% 
CI = 0.30 to 0.90, respectively) (Table 1). Tamoxifen users were 
50% more likely to have had a hysterectomy prior to tamoxifen 
use (OR = 1.56, 95% CI = 1.21 to 2.01); however, the majority of 
users (66%) had an intact uterus at tamoxifen initiation. After 
accounting for hysterectomy status, bilateral oophorectomy did 
not contribute to odds of tamoxifen use, though women who 
reported using unopposed estrogens (the recommended for-
mulation for women without a uterus) were less likely to use 
tamoxifen compared with never-users of postmenopausal hor-
mones (OR = 0.70, 95% CI = 0.51 to 0.95). More extensive family 
histories of breast cancer and higher BCRAT scores were strongly 










































Figure  1. A) Percent of tamoxifen users with a risk-benefit index (16,20) indi-
cating no, moderate, or strong evidence that the benefits of tamoxifen for the 
primary prevention of breast cancer and fracture exceed the risk of serious side 
effects (ie, endometrial cancer, stroke, pulmonary embolism, deep vein throm-
bosis, and cataract). Percentages are shown overall and according to hysterec-
tomy status, race, and age at tamoxifen initiation. B) Odds ratios (95% confidence 
intervals) for a favorable risk-benefit profile (moderate or strong evidence that 
benefits of tamoxifen outweigh the risks) according to hysterectomy status, race, 
and age at tamoxifen initiation. CI = confidence interval.






increases in tamoxifen use were observed among women with 
BCRAT scores of 3% to 6% (OR = 4.97, 95% CI = 3.57 to 6.24) or 
with more than one sister with breast cancer (OR  =  6.53, 95% 
CI = 4.66 to 9.12). Tamoxifen users were also more likely to have 
moderate (OR = 1.64, 95% CI = 1.22 to 2.19) or strong (OR = 4.33, 
95% CI = 3.27 to 5.74) evidence of benefit compared with non-
users. Women who reported having a breast biopsy were twice 
as likely to use tamoxifen compared with those with no biopsy 




OR (95% CI)* OR (95% CI)†No. (%) No. (%)
Total 788 (100.0) 3131 (100.0) N/A N/A
Education
 High school diploma or equivalent 101 (12.8) 430 (13.7) 0.93 (0.73 to 1.18) 0.72 (0.55 to 0.95)
 Some college 262 (33.2) 1009 (32.2) 1.02 (0.85 to 1.22) 0.91 (0.51 to 1.12)
 Four-year college degree or higher 420 (53.3) 1655 (52.9) 1.0 (reference) 1.0 (reference)
Race
 Non-Hispanic white 720 (91.4) 2717 (86.8) 1.0 (reference) 1.0 (reference)
 Black 32 (4.1) 215 (6.9) 0.54 (0.36 to 0.79) 0.41 (0.26 to 0.63)
 Hispanic 18 (2.3) 118 (3.8) 0.55 (0.33 to 0.92) 0.52 (0.30 to 0.90)
Smoking before index age
 Never 412 (52.3) 1688 (53.9) 1.0 (reference) 1.0 (reference)
 Former 306 (38.8) 1130 (36.1) 1.12 (0.94 to 1.32) 0.98 (0.81 to 1.18)
 Current 67 (8.5) 304 (9.7) 0.90 (0.67 to 1.19) 0.81 (0.59 to 1.12)
Hysterectomy before index age
 No 520 (66.0) 2302 (73.5) 1.0 (reference) 1.0 (reference)
 Yes 267 (33.9) 824 (26.3) 1.46 (1.23 to 1.73) 1.56 (1.21 to 2.01)
Bilateral oophorectomy before index age
 No 662 (84.0) 2746 (87.7) 1.0 (reference) 1.0 (reference)
 Yes 125 (15.9) 383 (12.2) 1.38 (1.10 to 1.73) 1.18 (0.86 to 1.62)
Postmenopausal hormone use before index age
 Never 482 (61.2) 1911 (61.0) 1.0 (reference) 1.0 (reference)
 Estrogen only (E) 142 (18.0) 544 (17.4) 1.02 (0.81 to 1.28) 0.70 (0.51 to 0.95)
 Both E and E+P 25 (3.2) 97 (3.1) 1.01 (0.64 to 1.60) 0.71 (0.42 to 1.31)
 Estrogen and progestin only (E+P) 120 (15.2) 523 (16.7) 0.92 (0.71 to 1.16) 1.00 (0.77 to 1.31)
Sister diagnosed with breast cancer before index age
 None 263 (33.4) 1594 (50.9) 1.0 (reference) 1.0 (reference)
 One sister 419 (53.2) 1420 (45.4) 1.94 (1.62 to 2.32) 1.89 (1.56 to 2.29)
 More than one sister 106 (13.5) 117 (3.7) 6.00 (4.43 to 8.14) 6.52 (4.66 to 9.12)
BCRAT score‡
 <1.67 18 (2.3) 259 (8.3) 0.32 (0.17 to 0.62) 0.31 (0.16 to 0.60)
 1.67–2.99 132 (16.8) 1429 (45.6) 1.0 (reference) 1.0 (reference)
 3.00–5.99 406 (51.5) 1138 (36.3) 5.04 (4.01 to 6.33) 4.97 (3.95 to 6.24)
 ≥6.00 228 (28.9) 302 (9.6) 13.27 (9.96 to 17.68) 13.37 (9.99 to 17.89)
 Mean score (SD), continuous trend 5.1 (2.4) 3.4 (1.9) 1.58 (1.50 to 1.65) 1.60 (1.53 to 1.68)
Risk-benefit index§
 No evidence of benefit 158 (20.1) 1012 (32.3) 1.0 (reference) 1.0 (reference)
 Moderate evidence of benefit 98 (12.4) 428 (13.7) 1.51 (1.14 to 2.00) 1.64 (1.22 to 2.19)
 Strong evidence of benefit 486 (61.7) 1406 (44.9) 3.70 (2.86 to 4.78) 4.33 (3.27 to 5.74)
 Not calculated 46 (5.8) 285 (9.1)
Breast biopsy history
 None 290 (36.8) 1843 (58.9) 1.0 (reference) 1.0 (reference)
 1 185 (23.5) 518 (16.5) 2.22 (1.80 to 2.75) 2.06 (1.65 to 2.56)
 >1 270 (34.3) 392 (12.5) 4.46 (3.62 to 5.49) 4.27 (3.44 to 5.29)
General health last 12 months
 Excellent 269 (34.1) 1247 (39.8) 1.0 (reference) 1.0 (reference)
 Very good 311 (39.5) 1161 (37.1) 1.25 (1.04 to 1.50) 1.27 (1.04 to 1.55)
 Good 154 (19.5) 557 (17.8) 1.29 (1.04 to 1.62) 1.18 (0.92 to 1.51)
 Fair 44 (5.6) 144 (4.6) 1.43 (1.00 to 2.06) 1.37 (0.91 to 2.06)
 Poor 10 (1.3) 20 (0.6) 2.37 (1.08 to 5.21) 2.77 (1.18 to 6.48)
* Adjusted for age and study enrollment year through matching. BCRAT = Breast Cancer Risk Assessment Tool; CI = confidence interval; N/A = not applicable; OR = odds ratio.
† Mutually adjusted for other variables in the table except BCRAT score or the risk-benefit index (composite variables).
‡ Multivariable model does not adjust for family history of breast cancer, race, or breast biopsy history (components of the BCRAT score). Continuous trend is the 
odds ratio for BCRAT score as a numeric parameter in multivariable models.
§ Multivariable model does not adjust for family history of breast cancer, race, hysterectomy status, or breast biopsy history (components of the BCRAT score or risk-
benefit index).






history (OR = 2.06, 95% CI = 1.65 to 2.56). Tamoxifen users were 
more likely to report worse general health, but were not more 
likely to smoke (Table 1).
Patterns with BCRAT scores persisted in analyses restricted 
to women with tamoxifen initiation within five or two years of 
enrollment (for whom risk scores calculated at enrollment were 
a better reflection of breast cancer risk at the time of tamoxifen 
initiation) (Supplementary Figure 2, available online). In sensi-
tivity analyses restricted to women with an index age within 
five years of study enrollment, tamoxifen associations with 
risk-benefit indices were attenuated but still apparent for mod-
erate and strong evidence categories (OR = 1.41, 95% CI = 0.93 to 
2.14 and OR = 3.21, 95% CI = 2.10 to 4.89, respectively) (data not 
shown).
Tamoxifen Discontinuation
At 4.5  years, 46% of tamoxifen users had discontinued use 
(Figure 2). Among former users, the median duration of tamox-
ifen use was 3.0 years. Women who reported using raloxifene 
after tamoxifen were 55% less likely to complete five years 
(OR = 0.45, 95% CI = 0.27 to 0.75) (Table 2). Women who had a 
sister with breast cancer before the index age or reported BRCA 
testing appeared 29% to 39% less likely to complete five years of 
tamoxifen, although these estimates did not meet the threshold 
for statistical significance. For every percentage point increase 
in BCRAT score, the odds of completing five years of tamoxifen 
increased by 7% (OR = 1.07, 95% CI = 1.00 to 1.15). Age at tamox-
ifen initiation, race, smoking, and menopausal status were 
not statistically significantly associated with discontinuation 
(Table 2). Five-year discontinuation rates across calendar years 
are provided in Supplementary Table 1 (available online).
Few women reported stroke (three tamoxifen users, four 
nonusers), TIA (eight tamoxifen users, 22 nonusers), or uter-
ine/endometrial cancer (two tamoxifen users, three nonusers) 
after the index age. Tamoxifen users were 49% more likely (95% 
CI  =  1.05 to 2.11) to report cataract (55 tamoxifen users, 179 
nonusers) compared with nonusers; cataract diagnosis was not 
statistically significantly related to discontinuation before five 
years (data not shown).
Discussion
In our sample of 788 women who used tamoxifen for breast 
cancer prevention outside of a clinical trial from 1986 to 2009, 
approximately one in five tamoxifen users had no evidence 
that the benefits were likely to exceed the risks. Absence of 
expected benefit was most pronounced for older women, 
African Americans, and those with an intact uterus. A  2011 
update to the risk-benefit tables (20) has recently been included 
in the USPSTF (8), American Society of Clinical Oncology (ASCO) 
(7), and the NCCN (21) Breast Cancer Risk Reduction guidelines. 
Dissemination of the risk-benefit tables will expand the tools 
available to providers for counseling women about the potential 
value of breast cancer chemoprevention.
In our analysis, 50% of tamoxifen users were premeno-
pausal. The risk-benefit index is more uniformly favorable for 
women younger than 50 years (16), and tamoxifen remains the 
only FDA-approved chemoprevention agent for premenopau-
sal women. Recent trials of aromatase inhibitors (23,24) show 
important benefits for breast cancer prevention; however, their 
use is limited to postmenopausal women. Until alternative ther-
apies for premenopausal women become available, tamoxifen 
will continue to have an important role in breast cancer primary 
prevention.
A recent systematic review of studies examining decision-
making surrounding tamoxifen use concluded that higher 
perceived breast cancer risk increased willingness to consider 
tamoxifen for prevention, but few other characteristics have 
been identified (25). Factors associated with actual tamoxifen 
use may differ from those related to hypothetical decision-mak-
ing. In our data, tamoxifen users were more likely than nonusers 
to report non-Hispanic white race, never using unopposed estro-
gens, stronger family histories of breast cancer, higher BCRAT 
scores, and worse general health status. We observed no statisti-
cally significant association with education, smoking status, or 
bilateral oophorectomy. These findings differ from studies that 
reported greater willingness to use tamoxifen among women 
who were less educated (26), used postmenopausal hormones 
(10), smoked (10), or had intact ovaries (27) and no association 
with general health or race (10,11,28). Three studies reported no 
association between BCRAT scores greater than or equal to vs 
less than 1.7 and tamoxifen-use (10,11,13), while our analysis 
and one other (12) observed positive associations using continu-
ous BCRAT scores.
Discontinuation of tamoxifen before the recommended five 
years (46%) was somewhat greater than the 24% to 36% non-
adherence reported in prevention trials (29). However, it is 
closely aligned with a recent metaregression estimate of 47.2% 
five-year discontinuation of tamoxifen as adjuvant endocrine 
therapy ([30], reviewed in [31]). Women who reported a family 
history of breast cancer, BRCA1/2 testing, or positive mutation 
status appeared less likely to complete five years of tamoxifen. 
Information on the efficacy of tamoxifen for chemoprevention 
among BRCA1/2 carriers is still limited based on small numbers 
of carriers in the NSABP P-1 trial (32). Race and smoking status 
were not statistically significantly associated with tamoxifen 
discontinuation in our analysis. However, the direction of the 
estimates was consistent with lower completion rates reported 
among minority race women and current smokers in the pre-
vention trials (33,34). In our sample, age was also not statisti-
cally significantly associated with tamoxifen discontinuation, 
although there was a suggested U-shaped association with the 
youngest and oldest women less likely to complete five years. 
Age older or younger than 48  years was not associated with 
Figure  2. Kaplan–Meier survival curve of discontinuation before five years 
among women taking tamoxifen for primary prevention of breast cancer.






compliance in the IBIS-1 prevention trial (33); however, women 
age 60 years and older had lower compliance in the NSABP P-1 
trial (34).
Limitations of this analysis include not having information 
on pulmonary embolism and deep vein thrombosis for subject 
selection; however, we excluded women who had other con-
ditions that could contraindicate tamoxifen use. Some char-
acteristics, such as BRCA1/2 testing and biopsy history, were 
assessed at enrollment rather than index age. However, the 
matched design ensured that equal time had elapsed since the 
index age and enrollment. Matching on age prohibited evalua-
tion of the association between age and tamoxifen use. In our 
sample, 5% of tamoxifen users were excluded for medical his-
tory of cataract, stroke, TIA, uterine or endometrial cancer as of 
the age tamoxifen use was initiated. Our a priori restriction to 
women who had no known contraindicating medical conditions 
prior to the index age precluded us from evaluating associations 
between these conditions and tamoxifen initiation.
We relied on self-reported information on tamoxifen use for 
breast cancer prevention and clinical trial participation, which 
has potential to introduce misclassification if women do not 
provide accurate reports. Although validation data are unavail-
able for the current study, previous reports have demonstrated 
90% to 94% agreement between self-reported tamoxifen use and 
medical records in the treatment context (35,36). Validation data 
for trial participation and information on the trial outcomes (ie, 
breast cancer prevention) were not available.
Tamoxifen also has other indications, including ovulation 
induction (37), retroperitoneal fibrosis (38), bipolar disorder 
(39), and osteoporosis prevention and treatment. In our sample, 
Table 2. Odds ratios and 95% confidence intervals for completion of 5 years or more of tamoxifen for chemoprevention according to Sister 
Study participant characteristics
Participant characteristics
Tamoxifen ≥5 y Tamoxifen <5 y
OR (95% CI)* OR (95% CI)†No. (%) No. (%)
Total 237 (100.0) 318 (100.0) N/A N/A
Age at tamoxifen initiation, y
 26–44 50 (21.1) 72 (22.6) 0.84 (0.51 to 1.37) 0.75 (0.44 to 1.28)
 45–49 62 (26.2) 74 (23.3) 1.01 (0.63 to 1.63) 0.98 (0.59 to 1.60)
 50–54 63 (26.6) 76 (23.9) 1.0 (reference) 1.0 (reference)
 55–59 34 (14.3) 47 (14.8) 0.87 (0.50 to 1.52) 0.93 (0.52 to 1.66)
 60–73 28 (11.8) 49 (15.4) 0.69 (0.39 to 1.22) 0.79 (0.43 to 1.46)
Race
 Non-Hispanic white 222 (93.7) 279 (87.7) 1.0 (reference) 1.0 (reference)
 Black 9 (3.8) 20 (6.3) 0.57 (0.25 to 1.27) 0.61 (0.27 to 1.40)
 Hispanic 3 (1.3) 10 (3.1) 0.38 (0.10 to 1.39) 0.33 (0.09 to 1.24)
Smoking status at tamoxifen initiation
 Never 121 (51.1) 151 (47.5) 1.0 (reference) 1.0 (reference)
 Former 94 (39.7) 129 (40.6) 0.91 (0.64 to 1.30) 0.90 (0.62 to 1.30)
 Current 21 (8.9) 37 (11.6) 0.71 (0.39 to 1.27) 0.75 (0.41 to 1.39)
Menopausal status at tamoxifen initiation
 Premenopausal 109 (46.0) 125 (39.3) 1.0 (reference) 1.0 (reference)
 Postmenopausal 76 (32.1) 118 (37.1) 0.74 (0.50 to 1.09) 0.77 (0.48 to 1.23)
BCRAT score at enrollment‡
 <1.67 1 (0.4) 15 (4.7) 0.10 (0.01 to 0.81) 0.08 (0.01 to 0.67)
 1.67–2.99 35 (14.8) 53 (16.7) 1.0 (reference) 1.0 (reference)
 3.00–5.99 115 (48.5) 156 (49.1) 1.13 (0.69 to 1.83) 1.19 (0.72 to 1.95)
 ≥6.00 85 (35.9) 92 (28.9) 1.41 (0.85 to 2.36) 1.60 (0.94 to 2.72)
 Mean score (SD), continuous trend 5.4 (2.3) 5.1 (2.7) 1.04 (0.97 to 1.11) 1.07 (1.00 to 1.15)
Raloxifene
 Never 197 (83.1) 236 (74.2) 1.0 (reference) 1.0 (reference)
 Yes, prior to tamoxifen start age 14 (5.9) 15 (4.7) 1.12 (0.53 to 2.37) 1.19 (0.55 to 2.60)
 Yes, after tamoxifen start age 26 (11.0) 67 (21.1) 0.47 (0.29 to 0.76) 0.45 (0.27 to 0.75)
Sister(s) diagnosed with breast cancer before starting tamoxifen
 No 87 (36.7) 90 (28.3) 1.0 (reference) 1.0 (reference)
 Yes, one sister 117 (49.4) 179 (56.3) 0.67 (0.46 to 0.98) 0.71 (0.48 to 1.04)
 Yes, more than one sister 33 (13.9) 49 (15.4) 0.70 (0.41 to 1.18) 0.76 (0.44 to 1.32)
BRCA1/2 testing
 No 208 (87.8) 262 (82.4) 1.0 (reference) 1.0 (reference)
 Yes 27 (11.4) 55 (17.3) 0.62 (0.38 to 1.02) 0.61 (0.36 to 1.02)
BRCA1/2 mutation carrier§
 No 25 (10.5) 31 (9.7) 1.0 (reference) 1.0 (reference)
 Yes 2 (0.8) 19 (6.0) 0.13 (0.03 to 0.62) N/A
* Odds ratio and 95% confidence interval among 555 women who reported formerly using tamoxifen (n = 515) or currently using tamoxifen and starting five or more 
years before study enrollment (n = 40). BCRAT = Breast Cancer Risk Assessment Tool; CI = confidence interval; N/A = not applicable; OR = odds ratio.
† Mutually adjusted for other variables in the table except BCRAT score (a composite variable) or BRCA1/2 mutation testing or carrier status (because of small sample 
sizes).
‡ Adjusted for smoking status, menopausal status, and raloxifene use.
§ Among women who reported undergoing BRCA1/2 testing.






osteoporosis diagnosis and raloxifene use were not associ-
ated with tamoxifen initiation, although tamoxifen users were 
more likely to have had a bone density scan within the last 
24 months. Raloxifene was approved for primary prevention of 
breast cancer in 2007 (40); the majority of study subjects were 
enrolled prior to this date. Raloxifene use after tamoxifen was 
associated with early discontinuation, potentially because of the 
availability of an alternative preventive therapy. Ninety-seven 
women reported starting tamoxifen prior to FDA approval; how-
ever, based on the highly favorable risk-benefit profiles of these 
women (Supplementary Table  1, available online) and overlap 
with the recruitment years for the prevention trials (initiated in 
1990 [4–6]), we included them as off-label use. Lastly, our analy-
sis was nested within a family-based cohort study and may not 
represent women at high risk of breast cancer because of other 
factors.
The Sister Study, a large cohort of women with a family his-
tory of breast cancer, provided a unique opportunity to evaluate 
tamoxifen use for chemoprevention outside of a clinical trial. 
Our findings suggest that although the majority of women who 
use tamoxifen for breast cancer prevention are likely to benefit, 
care should be directed toward evaluating risk-benefit profiles 
among women who are older, have an intact uterus, and are 
African American.
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